Abstract
This study focuses on the significant role between gut microbiota and lymph node metastasis (LNM) in colorectal cancer (CRC). By conducting 16S rRNA sequencing on fecal samples from 147 CRC patients and combining it with the linear discriminant analysis effect size algorithm, we successfully identified significant differences in the gut microbiota between patients with LNM and those with no lymph node metastasis (NLNM). Furthermore, using transcriptome data from 23 CRC patients, we constructed an immune cell infiltration matrix to deeply explore the biological functions associated with LNM. Eventually, using the characteristics of the gut microbiota associated with LNM, we developed random forest (RF) and multilayer perceptron (MLP) machine learning models to predict the LNM status of CRC patients. We identified 21 differentially abundant gut microbes between the two groups, among which Bacteroides plebeius, significantly enriched in the LNM group, is closely related to the upregulation of neutrophils and chemokine CXCL8 expression, and this bacterial species is also positively correlated with the enhancement of inosine monophosphate metabolism. The RF and MLP models constructed based on the LNM-associated gut microbiota showed good predictive efficacy in predicting LNM status in CRC. This study reveals that Bacteroides plebeius may play an important role in the progression of CRC, with its mechanism potentially involving changes in immune modulation and metabolic pathways. The classification model constructed based on gut microbiota characteristics can predict LNM status of CRC, providing a new perspective for personalized and precision treatment of CRC patients.IMPORTANCEThis study highlights the pivotal role of gut microbiota in lymph node metastasis (LNM) of colorectal cancer (CRC), identifying key microbial differences between LNM and NLNM groups. Our findings implicate Bacteroides plebeius in CRC progression via immune modulation and metabolic alterations. Moreover, machine learning models based on gut microbiota predict LNM status accurately, offering a novel approach for personalized CRC treatment.